Intravitreal complement inhibitor injections (IVCIs) for geographic atrophy appeared to be acceptable to most patients if they assumed the treatment had functional vision benefits, a cross-sectional ...

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous ...

A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today ...

No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more ...

What is IZERVAY™?IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration ...

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that results in progressive and irreversible vision loss, particularly in older adults. It occurs due to the ...

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...

Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...

While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...